Vicore Pharma Holding AB is an innovative clinical-stage pharmaceutical company dedicated to creating life-changing treatments in diseases where the AT2 (angiotensin II type 2) receptor has a central role in stopping and reversing disease pathology. The company is focused on establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF), and is developing C21, a first-in-class orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) for IPF. Additionally, Vicore is advancing Almee™, an investigational medical device in clinical development, which is a digital therapeutic based on cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis.

Vicore Pharma Holding AB (publ) engages in the research and development of pharmaceutical products for the treatments for rare lung diseases. The company is developing VP01, a small molecule compound for oral administration that is in phase II clinical trial for the treatment of interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), systemic sclerosis, and COVID-19; and VP02, a formulation and delivery route for an existing immunomodulatory compound, which is preclinical trials to treat patients with IPF. It has a cooperation and development agreement with Emeriti Bio AB; license agreement with Nanologica AB (publ); and a collaboration agreement with Alex Therapeutics AB for the development and clinical validation of a digital therapeutic (DTx) built on the Alex DTx platform. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Gothenburg, Sweden.

VICO

COM:VICOREPHARMA

Vicore Pharma Holding AB

Last Close

7.77

21/11 16:29

Market Cap

2.17B

Beta: -

Volume Today

319.83K

Avg: -

Analysis Not Available